MON-PP149: Magnesium and Body Composition are Associated with Mortality in Prevalent Hemodialysis Patients: Myth or Reality?

Garagarza, Cristina; Valente, Ana; Oliveira, T.; Caetano, Cristina; Ribeiro, Sandra; Silva, A.

doi:10.1016/s0261-5614(15)30581-1

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We then carefully read the full text of each of the remaining 37 studies. Finally, 13 studies involving 205,436 patients met the inclusion criteria [11,13,14,18–45] . As shown in Table 1, the studies that met the inclusion criteria were all conducted between 2007 and 2020, involving 205,436 patients.…”

Section: Resultsmentioning

confidence: 99%

“…Ishimura et al [18] ★★★★ ★ ★★★ 7 Markaki et al [19] ★★★ ★ ★★★ 6 Ortega et al [20] ★★★ ★ ★★★ 6 Broek et al [21] ★★★★ ★ ★★★ 7 Laecke et al [22] ★★★★ ★ ★★★ 7 Lacson et al [11] ★★★★ ★ ★★★ 7 Fein et al [23] ★★★★ ★ ★★★ 6 Sakaguchi et al [14] ★★★★ ★ ★★ 6 Li et al [24] ★★★★ ★ ★★★ 7 de Roij van Zuijdewijn et al [25] ★★★ ★ ★★★ 7 Matias et al [26] ★★★★ ★ ★★★ 7 Garagarza et al [27] ★★★ ★ ★★★ 6 Kurita et al [28] ★★★ ★ ★★★ 6 Yang et al [13] ★★★ ★ ★★★ 7 Cai et al [29] ★★★ ★ ★★★ 7 Ago et al [30] ★★★★ ★ ★★ 7 Hughes et al [31] ★★★★ ★ ★★★ 7 Lv et al [34] ★★★ ★ ★★★ 6 Ferrè et al [32] ★★★ ★ ★★★ 7 Schmaderer et al [35] ★★★ ★ ★★★ 7 Sato et al [36] ★★★★ ★ ★★★ 6 Selim et al [33] ★★★★ ★ ★★★ 7 de Francisco et al [37] ★★★ ★ ★★★ 7 Zhang et al [38] ★★★ ★ ★★★ 7 Ye et al [39] ★★★ ★ ★★★ 7 Li et al [40] ★★★★ ★ ★★ 6 Lu et al [41] ★★★ ★ ★★★ 6 Mizuiri et al [42] ★★★ ★ ★★★ 6 Wu et al [43] ★★★★ ★ ★★★ 7 Ogawa et al [44] ★★★ ★ ★★★ 7 Guan et al [45] ★★★ ★ ★★★ 7…”

Section: Study Queue Selection Comparability Results Measurement Leve...mentioning

confidence: 99%

“…Matias et al [26] 2015 Portugal 206 63.6 ± 14.3 48 mo Prospective HD All-cause and cardiovascular mortality 7 Garagarza et al [27] 2015 Portugal 605 69.9 81.7 mo Prospective HD All-cause mortality 6 Kurita et al [28] 2015 Japan 3276 61.7 ± 12.5 3 yrs Prospective HD All-cause mortality 6 Yang et al [13] 2016 China 10,692 56 ± 16 60 mo Retrospective PD All-cause mortality 7 Cai et al [29] 2016 China 253 58 ± 16 29 mo Retrospective PD All-cause and cardiovascular mortality 7 Ago et al [30] 2016 Japan 399 65.86 ± 11.8 12 mo Retrospective HD All-cause mortality 7 Hughes et al [31] 2016 United Kingdom 1306 67.7 3.07 yrs Prospective CKD All-cause mortality 7 Lv et al [34] 2016 China 93 65.3 ± 14.7 5 yrs Retrospective HD All-cause and cardiovascular mortality 6 Ferrè et al [32] 2017 United States 306 46.8 ± 69.0 12.3 yrs Retrospective CKD All-cause and cardiovascular mortality 7 Schmaderer et al [35] 2017 Germany 50 67.9 3 yrs Prospective HD All-cause mortality 7 Sato et al [36] 2017 Japan 253 68.8 ± 12.3 4 mo Retrospective HD All-cause and cardiovascular mortality 6 Selim et al [33] 2017 Republic of Macedonia 185 49.74 ± 14.71 5 yrs Prospective HD All-cause and cardiovascular mortality 7…”

Section: 32mentioning

confidence: 99%

“…Ishimura et al [18] 2007 0.261 (0.143, 0.477) †,x 0.485 (0.241, 0.975) †,x NR 0.983 (0.313, 3.086) †,x Markaki et al [19] 2012 NR 1.16 (0.34, 3.96) * ,x NR NR Ortega et al [20] 2013 1.5 (0.15, 14.7) †,x NR 0.4 (0.08, 2.5) †,x NR Broek et al [21] 2013 NR NR NR 0.64 (0.39, 1.05) †,x Laecke et al [22] 2013 NR 0.93 (0.89, 0.98) †,x NR NR Lacson et al [11] 2014 1.6 (1.3, 1.96) * ,x NR NR NR Fein et al [23] 2014 0.142 (0.0354, 0.2486) †,x 0.984 (0.9684, 0.9999) †,x NR NR Sakaguchi et al [14] 2014 2.04 (1.9, 2.18) * , ‡ 1.18 (1.07, 1.30) * , ‡ NR NR Li et al [24] 2015 1.28 (1.15, 1.42) * ,x 1.17 (1.05, 1.30) * ,x NR NR de Roij van Zuijdewijn et al [25] 2015 0.85 (0.77, 0.94) †,x 0.88 (0.78, 0.99) †,x 0.73 (0.62, 0.85) †,x 0.73 (0.62, 0.85) †,x Matias et al [26] 2015 NR 0.87 (0.68, 0.99) †,x NR 0.82 (0.72, 0.95) †,x Garagarza et al [27] 2015 NR 0.489 (0.36, 0.76) †,x NR NR Kurita et al [28] 2015 NR NR Yang et al [13] 2016 1.28 (1.09, 1.50) * ,x 1.21 (1.09, 1.50) * ,x NR NR Cai et al [29] 2016 0.041 (0.007, 0.223) †,x 0.075 (0.01, 0.552) †,x 0.007 (0.001, 0.081) †,x 0.003 (0, 0.055) †,x Ago et al [30] 2016 NR NR Hughes et al [31] 2016 NR 1.71 (1.27, 2.30) * ,x NR NR Lv et al [34] 2016 NR NR NR 5.617 (1.628, 19.381) †,x Ferrè et al [32] 2017 Schmaderer et al [35] 2017 0.54 (0.20, 1.46) †,x 0.35 (0.13, 0.97) †,x NR NR Sato et al [36] 2017 de Francisco et al [37] 2017 0.69 (0.54, 0.89) †,x 1.28 (0.97, 1.70) †,x NR NR Zhang et al [38] 2017 0.025 (0.001, 0.528) * , ‡ NR NR NR Ye et al [39] 2018 0.85 (0.71, 1.02) †,x 0.83 (0.68, 1.01) †,x 0.85 (0.67, 1.08) †,x 0.82 (0.64, 1.06) †,x Li et al [40] 2019 0.572 (0.338, 0.797) Lu et al [41] 2019 NR 0.017 (0.002, 0.197) †,x NR 0.011 (0.000, 0.269) †,x Mizuiri et al [42] 2019 1.88 (1.13, 3.08) * ,x 1.72 (1.00, 2.91) * ,x NR NR Wu et al [43] 2019 9.544 (5.372, 16.965)…”

Section: All-cause Mortality Cardiovascular Mortality Studymentioning

confidence: 99%

See 3 more Smart Citations

Associations between the serum magnesium and all-cause or cardiovascular mortality in chronic kidney disease and end-stage renal disease patients

Liu

Wang²

2021

Medicine

View full text Add to dashboard Cite

Background:Some studies have found that hypomagnesemia is associated with vascular calcification, atherosclerosis, and cardiovascular disease, which may lead to increased mortality in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) who need to maintain hemodialysis (HD). However, the conclusion of these studies remain controversial.Methods:Relevant literature was retrieved from the database of Cochrane library, PubMed, EMBASE, and CNKI until December 2020, without any language restrictions. The data was analyzed using the Stata 12.0 software.Results:A total of 31 studies were included, involving 205436 participants. The results showed that after multivariable adjusted, hypomagnesemia was significant associated with the risk of all-cause mortality in patients with CKD and end-stage renal disease (ESRD) (hazard ratios [HR] 1.955; 95% confidence interval (95% CI) 1.511-2.528; P = .000; hypomagnesemia vs normal magnesium or hypermagnesemia). In contrast, in patients with CKD and ESRD, hypermagnesemia was negatively correlated with all-cause mortality (HR 0.873; 95% CI 0.793-0.960; P = .005) (per unit increase). Moreover, in the adjusted model, it was observed that hypermagnesemia was significantly associated with a reduced risk of cardiovascular death (HR 0.598; 95% CI 0.094-1.102, P = .020). In addition, subgroup analysis found that hypomagnesemia was closely related to the increase of all-cause mortality in HD patients (HR 1.799; 95% CI 1.375-2.354; P = .000) (hypomagnesemia vs normal magnesium or hypermagnesemia).Conclusion:Our results show that hypomagnesemia is significantly associated with cardiovascular and all-cause mortality in maintenance HD patients. Further studies should be conducted to evaluate the benefits of magnesium correction in maintenance dialysis patients with hypomagnesemia.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Study Queue Selection Comparability Results Measurement Leve...mentioning

confidence: 99%

Section: 32mentioning

confidence: 99%

Section: All-cause Mortality Cardiovascular Mortality Studymentioning

confidence: 99%

See 2 more Smart Citations

Associations between the serum magnesium and all-cause or cardiovascular mortality in chronic kidney disease and end-stage renal disease patients

Liu

Wang²

2021

Medicine

View full text Add to dashboard Cite

show abstract

Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis

Xiong

Min

et al. 2019

J Nephrol

View full text Add to dashboard Cite

Association between hypomagnesemia and mortality among dialysis patients: a systematic review and meta-analysis

Huang

Yang

Hung

et al. 2022

PeerJ

View full text Add to dashboard Cite

Background Malnutrition-inflammation-atherosclerosis (MIA) syndrome is caused by the inflammatory cytokines in end stage renal disease (ESRD) patients, and MIA complex-related factors may be associated with hypomagnesemia and mortality. However, the association between serum magnesium level and mortality for dialysis patients is still not clear. Additionally, no meta-analysis has investigated the impact of serum magnesium on peritoneal dialysis and hemodialysis, separately. Methods We searched published studies in PubMed, Embase, Cochrane, Collaboration Central Register of Controlled Clinical Trials, and Cochrane Systematic Reviews through April 2022. Studies associated with serum magnesium and all-cause mortality or cardiovascular (CV) mortality in ESRD on kidney replacement therapy (KRT) patients were included. A hazard ratio (HR) with 95% confidence intervals (CI) was used to report the outcomes. Results Twenty-one studies involving 55,232 patients were included. Overall, there was a significant association between hypomagnesemia and all-cause mortality for dialysis patients (HR: 1.67, 95% CI [1.412–2.00], p < 0.001; certainty of evidence: moderate) using a mixed unadjusted and adjusted HR for analysis. There was also a significantly increased risk of CV mortality for individuals with hypomagnesemia compared with the non-hypomagnesemia group (HR 1.56, 95% CI [1.08–2.25], p < 0.001; certainty of evidence: moderate). In addition, a subgroup analysis demonstrated that hypomagnesemia was associated with a high risk of both all-cause mortality and CV mortality (all-cause mortality, HR:1.80, 95% CI [1.48–2.19]; CV mortality, HR:1.84, 95% CI [1.10–3.07]) in hemodialysis (HD) patients, but not in participants receiving peritoneal dialysis (PD; all-cause mortality, HR:1.26, 95% CI [0.84–1.91]; CV mortality, HR:0.66, 95% CI [0.22–2.00]). The systematic review protocol was prespecified and registered in PROSPERO [CRD42021256187]. Conclusions Hypomagnesemia may be a significant risk factor for all-cause mortality and CV mortality in KRT patients, especially in those receiving hemodialysis. However, because of the limited certainty of evidence, more studies are required to investigate this association.

show abstract

MON-PP149: Magnesium and Body Composition are Associated with Mortality in Prevalent Hemodialysis Patients: Myth or Reality?

Cited by 3 publications

References 0 publications

Associations between the serum magnesium and all-cause or cardiovascular mortality in chronic kidney disease and end-stage renal disease patients

Associations between the serum magnesium and all-cause or cardiovascular mortality in chronic kidney disease and end-stage renal disease patients

Serum magnesium, mortality, and cardiovascular disease in chronic kidney disease and end-stage renal disease patients: a systematic review and meta-analysis

Association between hypomagnesemia and mortality among dialysis patients: a systematic review and meta-analysis

Contact Info

Product

Resources

About